Trial
NCT02441517
A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Astellas Pharma Global Development, Inc.
Collaborators
Medivation, Inc.
Condition
Metastatic Castration Resistant Prostate Cancer
Intervention
Enzalutamide
Why stopped
The study is closed early due to lck of enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-19